Inhibition of β-catenin results in decreased expression of its downstream targets, MMP-9, C-Myc, and cyclin D1, which suppress cell cycle progression, cell proliferation, and metastasis in prostate cancer [8] and hepatocellular carcinoma [9]. Here, MMP9 is linked to hepatocellular carcinoma.